PhD student in Bioethics & Health Policy at @JohnsHopkinsSPH @bermaninstitute | psychedelic ethics 🌱, research ethics

Joined March 2023
Working on getting a bibliography of sorts for psychedelic ethics/philosophy papers together - sharing in case it comes in useful for anyone else! Ongoing project & please feel free to let me know if I've missed something 🌿 katcheung.com/psychedelic-et…
9
19
75
5,959
New paper in JME Practical Bioethics: Katherine Cheung @Katherine_Chg, Edward Jacobs @eddietalksdrugs, and David Yaden @ExistWell review the ethics of psychedelic clinical trials and flag key concerns to resolve as psychedelics move toward real-world care. jmepb.bmj.com/content/2/4/e0…
3
9
36
1,792
Have you received psychedelic therapy through a legal pathway in Canada? 🇨🇦 We’re recruiting for a study in collaboration with the University of Ottawa @uOttawa. Share your experience in a 15–25 min survey: redcap.link/pace-ca #PsychedelicResearch #LivedExperience
3
2
1
3
118
Katherine Cheung retweeted
A comprehensive review of bioethical progress and need for further work on psychedelic research and potential clinical applications across screening, informed consent, dosing, follow-up, & more. Work led by @Katherine_Chg w/ @eddietalksdrugs and me. Check out the thread and link:
A growing body of bioethical work has examined ethical issues related to the use of psychedelics in clinical research. With @eddietalksdrugs and @ExistWell, we try to take stock in our state-of-the-field review, published in JME Practical Bioethics.
1
2
9
494
A growing body of bioethical work has examined ethical issues related to the use of psychedelics in clinical research. With @eddietalksdrugs and @ExistWell, we try to take stock in our state-of-the-field review, published in JME Practical Bioethics.
1
8
1
22
1,153
While we have focused our review on the ethical challenges relevant to clinical trials, many of the considerations we discuss will remain relevant as psychedelics move towards clinical applications.
1
4
42
Katherine Cheung retweeted
Meeting with scientists, clinicians, and bioethicists at @JHUBloombergCtr to discuss practical ethical guidelines for clinical applications of psychedelics. Meeting led by @eddietalksdrugs & @Katherine_Chg with @briandavidearp and I glad to see @psychedelethics doing applied work
3
6
9
724
We are thrilled to share a major milestone for the Johns Hopkins Center for Psychedelic and Consciousness Research: @CeydaSayali, PhD, has received an R01 award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) — the first R01 awarded to an investigator at our Center. The study will test a novel treatment approach for alcohol use disorder (AUD) combining psilocybin with personalized repetitive transcranial magnetic stimulation (rTMS). This is the first study to investigate this combination for AUD, with rTMS targets individualized using fMRI to identify each participant’s brain circuitry involved in regulating alcohol craving. Using fMRI and TMS-EEG, the study will also examine how this combined intervention changes the neural mechanisms underlying craving, cognitive control, and treatment response. By integrating psychedelic pharmacology, personalized brain stimulation, and multimodal neuroscience, this work aims to advance both treatment development and our understanding of how brain-based interventions can reduce problematic alcohol use. Congratulations to Dr. Sayalı and the research team on this important achievement and exciting new direction for the Center.
4
22
4
108
6,137
Katherine Cheung retweeted
The first completely on-site preclinical animal study from @JHPsychedelics. An immensely valuable collaboration with Division of Behavioral Biology. So grateful that I got to lead it and work with what can only be called the dream team! Unroll the tweet below for deets 📜
New paper led by @PraachiTiwari, a former postdoc in @TheYadenLab, now faculty at Div of Behavioral Bio & @JHPsychedelics (also w/ @CassieMoorePhD, Brian Jenkins, Elise Weerts, me). We examined how psilocybin affects a broader range of spontaneous behaviors in rats than HTR...
6
13
1,198
New paper – Validating and Creating a Short-Form of the Persisting Effects Questionnaire: A Measure of Positive and Negative Outcomes from Psychedelic Experiences The Persisting Effects Questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic experiences. While commonly used, the PEQ has never been formally validated, and is time-intensive and complex for both participants and researchers. Using a multi-study approach, CPCR researchers created and validated the Persisting Effects Questionnaire – Short Form (PEQ-SF), a scale that is more easily understood and reduces burden for study teams and participants. Read the paper here: journals.sagepub.com/doi/10.…
8
2
18
2,452
Katherine Cheung retweeted
Representing @TheYadenLab at @JHPsychedelics & @psychedelethics at @FDA. Postdoc Eddie Jacobs @eddietalksdrugs spoke to how the evidence on psychedelic treatments comes from clinical trials, so those safeguards should be used for initial roll-out, to be adjusted based on data…
3
9
1
38
1,928
Katherine Cheung retweeted
Psychedelic treatments are getting leaner as they approach licensing. Our (@IanRou of @PsyPANglobal, @HattiWells, and @drrosalindwatts) new Perspective in @TheCJPsych argues this gives us (more) reason to pay attention to patients’ social/relational environments🧵
1
4
1
13
773
Katherine Cheung retweeted
Great article in Scientific American on the Hopkins Post Psychedelic Difficulties Clinic!
1
14
38
3,755
Congratulations to Dr. @PraachiTiwari on her promotion to faculty at the Johns Hopkins University School of Medicine! Dr. Tiwari joins the Division of Behavioral Biology and the Center for Psychedelic and Consciousness Research, where she will conduct both preclinical neuroscience and clinical studies to explore translational research on psychedelics.
6
16
1
116
5,242